ducovest

XVIPF:OTC-Xvivo Perfusion AB (publ) (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 51.16

Change

0.00 (0.00)%

Market Cap

USD 1.59B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden, the United States, the Netherlands, Italy, North and South America, Europe, the Middle East, Africa, the Asia Pacific, and Oceania. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. The company was incorporated in 1998 and is headquartered in Mölndal, Sweden.

Company Website : https://www.xvivogroup.com

Currency: USD

Country : USA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-24 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
SEMHF Siemens Healthineers AG

N/A

 USD 62.09B
SMMNY Siemens Healthineers AG ADR

+0.59 (+2.21%)

 USD 61.88B
RYLPF Koninklijke Philips N.V

N/A

 USD 28.80B
SONVF Sonova Holding AG

N/A

 USD 20.54B
SNNUF Smith & Nephew plc

N/A

 USD 13.42B
WILLF Demant A/S

-2.92 (-7.07%)

 USD 9.10B
GNGBF Getinge AB

N/A

 USD 6.02B
AMBBY Ambu A/S

N/A

 USD 5.26B
AMBFF Ambu A/S

N/A

 USD 5.26B
GGNDF GN Store Nord A/S

N/A

 USD 3.66B

ETFs Containing XVIPF

RUBY-U:CA RBC U.S. Banks Yield Inde.. 7.27 % 0.00 %

N/A

 N/A
IUS2:F iShares S&P U.S. Banks UC.. 4.19 % 0.00 %

-0.08 (0.00%)

 N/A
IAT iShares U.S. Regional Ban.. 4.17 % 0.42 %

-0.46 (0.00%)

 N/A
BNKS:LSE iShares S&P U.S. Banks ET.. 4.16 % 0.00 %

-0.05 (0.00%)

 N/A
FBU:CA 2.78 % 0.84 %

N/A

 N/A
UINC:LSE First Trust US Equity Inc.. 2.53 % 0.00 %

+0.50 (+0.00%)

 USD 0.31B
KRS 2.30 % 0.95 %

N/A

 N/A
KRU 2.30 % 0.95 %

N/A

 N/A
MVIN 2.28 % 0.55 %

N/A

 N/A
KRE SPDR® S&P Regional Banki.. 2.23 % 0.35 %

-0.77 (0.00%)

 N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 124.39% 93% A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 124.39% 93% A 93% A
Trailing 12 Months  
Capital Gain 103.02% 91% A- 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 103.02% 91% A- 92% A
Trailing 5 Years  
Capital Gain 199.18% 92% A 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 199.18% 92% A 91% A-
Average Annual (5 Year Horizon)  
Capital Gain 38.42% 75% C 73% C
Dividend Return 38.42% 75% C 72% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 78.06% 46% F 39% F
Risk Adjusted Return 49.21% 95% A 84% B
Market Capitalization 1.59B 87% B+ 77% C+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.